Andy Sheldon
Andy Sheldon is a veteran of the pharmaceutical and biotechnology sectors with over 45 years of experience working in senior roles at SmithKline, Rhone-Merieux, ShireBiochem and Medicago. Andy served as CEO at Medicago from 2003 to 2017 where he led the team that built and validated vaccine facilities in Quebec and North Carolina. As CEO, Andy attracted over 1B$ in financing, grew the company to 400 employees, completed multiple phases 2 trials and commenced the phase 3 trial for quadrivalent Influenza. In other leadership roles, Andy secured FDA licencing for vaccines and successfully negotiated commercial deals in the North America, Europe and Asia.
Andy’s accomplishments have been formally recognized on several occasions with awards that include Vaccine CEO of the Year in 2012, Médaille de la ville de Quebec in 2018, Prix de Rayonnemnt Quebec and Grands Diplômées de l’université in Laval 2017. Andy holds a Bachelor’s degree in agricultural sciences from Université Laval and a Bachelor’s of Science degree with honors in biological sciences from the University of East Anglia.
Andy Sheldon has served on many boards over his career and currently Board President at both Quebec International and Biotwin. Andy was elected to the Biologics Manufacturing Centre Board of Directors in December 2023